Galacto-N-biose is neuroprotective against glutamate-induced excitotoxicity in vitro.

[1]  Jinghuan Li,et al.  Targeting blood-brain-barrier transcytosis – perspectives for drug delivery , 2017, Neuropharmacology.

[2]  A. Traweger,et al.  Pharmaceutical Targeting of the Brain. , 2016, Current pharmaceutical design.

[3]  Lauren E. Salminen,et al.  Oxidative stress and genetic markers of suboptimal antioxidant defense in the aging brain: a theoretical review , 2014, Reviews in the neurosciences.

[4]  Y. Shinoda,et al.  BDNF enhances spontaneous and activity-dependent neurotransmitter release at excitatory terminals but not at inhibitory terminals in hippocampal neurons , 2014, Front. Synaptic Neurosci..

[5]  L. Schneider,et al.  Lack of evidence for the efficacy of memantine in mild Alzheimer disease. , 2011, Archives of neurology.

[6]  A. Moran,et al.  Sweet-talk: role of host glycosylation in bacterial pathogenesis of the gastrointestinal tract , 2011, Gut.

[7]  H. Hirase,et al.  Calcium-dependent activator protein for secretion 2 (CAPS2) promotes BDNF secretion and is critical for the development of GABAergic interneuron network , 2010, Proceedings of the National Academy of Sciences.

[8]  Y. Shinoda,et al.  Persistent Synapse Loss Induced by Repetitive LTD in Developing Rat Hippocampal Neurons , 2010, PloS one.

[9]  A. Lau,et al.  Glutamate receptors, neurotoxicity and neurodegeneration , 2010, Pflügers Archiv - European Journal of Physiology.

[10]  Z. Qin,et al.  Molecular and cellular mechanisms of excitotoxic neuronal death , 2010, Apoptosis.

[11]  M. Tymianski,et al.  Calcium, ischemia and excitotoxicity. , 2010, Cell calcium.

[12]  M. Nishimoto,et al.  One-pot enzymatic production of beta-D-galactopyranosyl-(1-->3)-2-acetamido-2-deoxy-D-galactose (galacto-N-biose) from sucrose and 2-acetamido-2-deoxy-D-galactose (N-acetylgalactosamine). , 2009, Carbohydrate research.

[13]  J. Sepulcre,et al.  Memantine induces reversible neurologic impairment in patients with MS , 2009, Neurology.

[14]  Z. Qin,et al.  Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases , 2009, Acta Pharmacologica Sinica.

[15]  Peng Huang,et al.  Redox regulation of cell survival. , 2008, Antioxidants & redox signaling.

[16]  L. Massieu,et al.  Excitotoxic neuronal death and the pathogenesis of Huntington's disease. , 2008, Archives of Medical Research.

[17]  M. Nishimoto,et al.  Identification of N-Acetylhexosamine 1-Kinase in the Complete Lacto-N-Biose I/Galacto-N-Biose Metabolic Pathway in Bifidobacterium longum , 2007, Applied and Environmental Microbiology.

[18]  W. Robberecht,et al.  The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis. , 2006, Biochimica et biophysica acta.

[19]  Claire Mount,et al.  Alzheimer disease: progress or profit? , 2006, Nature Medicine.

[20]  D. Hovda,et al.  Evidence for Energy Failure following Irreversible Traumatic Brain Injury , 1999, Annals of the New York Academy of Sciences.

[21]  M. Moskowitz,et al.  Pathobiology of ischaemic stroke: an integrated view , 1999, Trends in Neurosciences.

[22]  G. Albers,et al.  Dose escalation study of the NMDA glycine-site antagonist licostinel in acute ischemic stroke. , 1999, Stroke.

[23]  K. Savolainen,et al.  Glutamate-stimulated ROS production in neuronal cultures: interactions with lead and the cholinergic system. , 1998, Neurotoxicology.

[24]  J. Taylor‐Papadimitriou,et al.  Comparison of O-Linked Carbohydrate Chains in MUC-1 Mucin from Normal Breast Epithelial Cell Lines and Breast Carcinoma Cell Lines: , 1996, The Journal of Biological Chemistry.

[25]  Richard H. P. Porter,et al.  Glutamate and Parkinson’s disease , 1996, Molecular Neurobiology.

[26]  J. Grotta,et al.  Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischemic stroke. Results of a phase IIa randomized trial. , 1995, Stroke.

[27]  K. Lees,et al.  Clinical experience with excitatory amino acid antagonist drugs. , 1995, Stroke.

[28]  W. Löscher,et al.  The behavioural effects of MK-801 in rats: involvement of dopaminergic, serotonergic and noradrenergic systems. , 1992, European journal of pharmacology.

[29]  D. Choi,et al.  Calcium and excitotoxic neuronal injury , 1991, Journal of the Neurological Sciences.

[30]  L. Facci,et al.  Hypoglycemic neurotoxicity in vitro: Involvement of excitatory amino acid receptors and attenuation by monosialoganglioside GM1 , 1990, Neuroscience.

[31]  S. Rothman,et al.  Glutamate neurotoxicity in vitro: antagonist pharmacology and intracellular calcium concentrations , 1990, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[32]  R. C. Collins,et al.  Excitotoxic mechanisms of epileptic brain damage. , 1986, Advances in neurology.